[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs]

Bull Cancer. 2017 Sep;104(9):800-806. doi: 10.1016/j.bulcan.2017.06.006. Epub 2017 Jul 27.
[Article in French]
No abstract available

Keywords: Approche phénotypique; Bayesian; Bayésien; Bevacizumab; Bévacizumab; Imatinib; Phenotypical approach; Regorafenib; Régorafenib; Suivi thérapeutique pharmacologique; Therapeutic drug monitoring.

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Bayes Theorem
  • Bevacizumab / pharmacokinetics
  • Bevacizumab / therapeutic use
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / metabolism
  • Drug Monitoring*
  • Erlotinib Hydrochloride / pharmacokinetics
  • Erlotinib Hydrochloride / therapeutic use
  • Humans
  • Imatinib Mesylate / pharmacokinetics
  • Imatinib Mesylate / therapeutic use
  • Liver / metabolism
  • Neoplasms / drug therapy*
  • Phenylurea Compounds / pharmacokinetics
  • Phenylurea Compounds / therapeutic use
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Pyridines
  • regorafenib
  • Bevacizumab
  • Imatinib Mesylate
  • Erlotinib Hydrochloride